Zhejiang Huakang Pharmaceutical Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Deshui Chen

Chief Executive Officer (CEO)

CN¥1.5m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	15.9%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

May 02

CEO

Deshui Chen (53 yo)

no data

Permanencia

CN¥1,505,800

Compensación

Mr. Deshui Chen is Chairman of the Board & GM of Zhejiang Huakang Pharmaceutical Co. Ltd.

Zhejiang Huakang Pharmaceutical Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Zhejiang Huakang Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

No independent directors

Recent updates

We Think That There Are Some Issues For Zhejiang Huakang Pharmaceutical (SHSE:605077) Beyond Its Promising Earnings

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.39 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.63 (vs CN¥1.40 in FY 2022)

Zhejiang Huakang Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Zhejiang Huakang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 17%

Zhejiang Huakang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Now 20% undervalued after recent price drop

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.49 in 3Q 2022)

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: CN¥0.42 (vs CN¥0.40 in 2Q 2022)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥1.40 (vs CN¥1.07 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.49 (vs CN¥0.84 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.25 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.38 in 1Q 2021)

No independent directors

Full year 2021 earnings released: EPS: CN¥1.50 (vs CN¥2.51 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.45 (vs CN¥2.88 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.69 (vs CN¥0.40 in 2Q 2020)

Tangshan Jinkun Chemical Co., Ltd. agreed to acquire Tangshan Huayue Food Technology Co., Ltd. from Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) for CNY 17.5 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥3.51 (vs CN¥3.09 in FY 2019)

Investor sentiment deteriorated over the past week

CEO

Permanencia

Compensación